28 thoughts on “🏴‍☠️ CARA THERAPEUTICS USD (CARA-USD)”

  1. CARA is “In Play”

    Cara Therapeutics reports patient enrollment for KALM-2 Phase 3 Global Trial of KORSUVA increased approximately 20% to maintain > 90% statistical power:

    • Co announced the completion of an interim statistical assessment of its pivotal KALM-2 Phase 3 global clinical trial of KORSUVA (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus.
    • Based on the Independent Data Monitoring Committee’s (IDMC) recommendation, the size of the trial will be increased by approximately 20 percent, from an original enrollment target of 350 patients to 430 patients, to maintain the pre-specified statistical power of 90 percent or greater on the trial’s primary endpoint. The IDMC charter allowed for the trial size to be increased up to a maximum of 500 patients. The IDMC’s recommendation was based on the results of a prespecified interim conditional power assessment conducted after approximately 50 percent of the targeted patient number completed the designated 12-week treatment period.

    Acquired CARA THERAPEUTICS USD (CARA-USD). via ROBINHOOD at approximately 18.64. (Shares: 1) bringing the Average Price Paid (APP) to about 18.64.

    https://www.facebook.com/groups/493863300973045/permalink/853620751663963/

  2. CARA IS “IN PLAY”

    Cara Therapeutics announces publication in the New England Journal of Medicine The paper, titled “A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus,” summarizes data from 378 patients, randomized to receive intravenous bolus difelikefalin at a dose of 0.5 mcg/kg or placebo at the end of each dialysis session, administered over a 12-week treatment period. Overall, 51.9% of patients in the difelikefalin group achieved the pre-specified primary outcome of a three point or greater improvement in the weekly mean of the daily worst itch intensity numeric rating scale (WI-NRS) versus 30.9% in the placebo group at week 12. In an additional analysis conducted for NEJM, the imputed proportion of patients achieving the primary outcome was 49.1% in the difelikefalin group, as compared to 27.9% in the placebo group (p<0.001) at week 12. Difelikefalin treatment also resulted in statistically significant improvements in the proportion of patients achieving a four point or greater improvement in WI-NRS, as well as in itch-related quality of life measures, as assessed by the 5-D itch and Skindex-10 scales, from baseline to week 12. Diarrhea, dizziness, and vomiting were more common in the difelikefalin group than the placebo group, consistent with earlier clinical trials of difelikefalin in hemodialysis patients with CKD-aP.

    Adjusted Sell Stop to 21.10. from ASSESSING.

    https://www.facebook.com/groups/493863300973045/permalink/853620751663963/

  3. CARA IS IN PLAY

    Cara Therapeutics announced positive topline results from its Phase 2 dose-ranging trial of Oral KORSUVA for the treatment of pruritus in patients with stage III-V (moderate-to-severe) chronic kidney disease

    Patients treated with the 1 mg tablet strength of Oral KORSUVA achieved the primary endpoint of statistically significant reduction in weekly mean of the daily WI-NRS scores vs. placebo after the 12-week treatment period (-4.4 KORSUVA vs. -3.3 placebo, p=0.018). The treatment effect was statistically significant after two weeks of treatment and sustained through the 12-week treatment period.

    The proportion of patients on 1 mg tablet strength achieving a 3 point or greater improvement from baseline in the weekly mean of the daily WI-NRS score at week 12 was 72% vs. 58% for placebo but did not achieve statistical significance.

    Adjusted Buy Stop to 16.97. from 26.59.

    Adjusted Sell Stop to ASSESSING. from 25.77.

    Converted 100% of Investment/Trade Money at approximately 25.77. (Shares: 12) generating about +‭15.3536% of NEW Commission FREE Cash Reserve.

    https://www.facebook.com/groups/493863300973045/permalink/853620751663963/

  4. #CARA IS IN PLAY

    Adjusted Buy Stop to 13.26. from 13.32.

    Adjusted Sell Stop to ASSESSING. from 12.50.

    Acquired at approximately 13.32. (Shares: 75) bringing the Average Price Paid (APP) to about 13.32.

    Converted 100% of Investment/Trade Money at approximately 12.50. (Shares: 5) generating about +13.6364% of NEW Commission FREE Cash Reserve.

    OPTIONS ASSESSMENT:
    CARA JAN 21 2022 $2.50 PUT
    CARA JAN 21 2022 $35.00 CALL

    https://www.facebook.com/groups/493863300973045/permalink/853620751663963/

  5. #CARA IS IN PLAY

    If you like to make money, then do what I do; not what I say

    Adjusted Multiplier to 67.549597. from 69.000000.

    Adjusted Buy Stop to 14.80. from 14.37.

    Adjusted Sell Stop to 13.99. from ASSESSING.

    Acquired at approximately 14.37. (Shares: 69.000000) bringing the Average Price Paid (APP) to about 14.37.

    Transferred 100% of Trade Money to Investment Money (Shares: 69.000000) bringing the Average Price Paid (APP) to about 13.63.

    Converted 100% of Investment/Trade Money at approximately ASSESSING. (Shares: ASSESSING) generating about +ASSESSING% of NEW Commission FREE Cash Reserve.

    https://www.facebook.com/groups/493863300973045/?post_id=853620751663963

  6. #CARA IS IN PLAY

    Multiplier (X) to 9.249700. from 67.549597.

    Buy Stop Limit (BSL) to 15.90. from 14.80.

    Sell Stop Limit (SSL) to 15.14. from 13.99.

    Converted Cash Reserve (CR) to Trade (T) at approximately 14.80. (Share: 67) bringing the Average Price Paid (APP) to about 14.80.

    Converted Trade (T) to Investment (I) (Share: 67) bringing the Average Price Paid (APP) to about 14.80.

    Converted Investment (I) to Cash Reserve (CR) at approximately 13.99. (Share: 219) generating about +2.64% ROI (Return on Investment).

    Just to reiterate, I placed the following order(s):
    + Buy 9. Shares @ 15.90; Limit: 15.90. & Stop: 15.89.
    – Sell 67. Shares @ 15.14; Limit 15.14. & Stop: 15.15.

    https://www.facebook.com/groups/493863300973045/?post_id=853620751663963

  7. #CARA IS IN PLAY

    Multiplier (X) to 8.438973. from 9.249700.

    Buy Stop Limit (BSL) to 17.43. from 15.90.

    Sell Stop Limit (SSL) to 16.56. from 15.14.

    Converted Cash Reserve (CR) to Trade (T) at approximately 15.90. (Share: 9) bringing the Average Price Paid (APP) to about 15.90.

    Converted Trade (T) to Investment (I) (Share: 9) bringing the Average Price Paid (APP) to about 14.93.

    Just to reiterate, I placed the following order(s):
    + Buy 8. Shares @ 17.43; Limit: 17.43. & Stop: 17.42.
    – Sell 76. Shares @ 16.56; Limit 16.56. & Stop: 16.57.

    https://www.facebook.com/groups/493863300973045/?post_id=853620751663963

  8. #CARA IS IN PLAY

    Multiplier (X) to 15.176299. from 8.438973.

    Buy Stop Limit (BSL) to 17.85. from 17.43.

    Sell Stop Limit (SSL) to ASSESSING. from 16.56.

    Converted Cash Reserve (CR) to Trade (T) at approximately 17.43. (Share: 8) bringing the Average Price Paid (APP) to about 17.43.

    Converted Investment (I) to Cash Reserve (CR) at approximately 16.56. (Share: 76) generating about +10.92% ROI (Return on Investment).

    Just to reiterate, I placed the following order(s):
    + Buy 15. Shares @ 17.85; Limit: 17.85. & Stop: 17.84.

    https://www.facebook.com/groups/493863300973045/?post_id=853620751663963

  9. #CARA IS IN PLAY

    Multiplier (X) to 17.831942. from 19.229489.

    Buy Stop Limit (BSL) to 15.19. from 14.09.

    Sell Stop Limit (SSL) to 14.84. from ASSESSING.

    Converted Cash Reserve (CR) to Trade (T) at approximately 14.09. (Share: 19) bringing the Average Price Paid (APP) to about 16.3456.

    Converted Trade (T) to Investment (I) (Share: 23) bringing the Average Price Paid (APP) to about 14.7469.

    Just to reiterate, I placed the following order(s):
    + Buy 17. Shares @ Limit Price: 15.19.
    + Sell 23. Shares @ Limit Price: 14.84.

    https://www.facebook.com/groups/493863300973045/permalink/853620751663963

  10. #CARA IS IN PLAY

    Multiplier (X) to 17.788550. from 17.831942.

    Buy Stop Limit (BSL) to 15.08. from 15.19.

    Sell Stop Limit (SSL) to XIIMM. from 14.84.

    Converted Cash Reserve (CR) to Trade (T) at approximately 15.19. (Share: 17) bringing the Average Price Paid (APP) to about 16.6827.

    Converted Investment (I) to Cash Reserve (CR) at approximately 14.84. (Share: 23) generating about +0.65% ROI (Return on Investment).

    Just to reiterate, I placed the following order(s):
    + Buy 17. Shares @ Limit Price: 15.08.

    Data:
    http://xiimm.net/collective/2021/01/04/cara-therapeutics-usd-cara-usd/

    Graphics:
    http://xiimm.net/collective/cara/

Leave a Reply